Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Endometrial Cancer Specialty Channel

Endometrial Cancer
Specialty Channel
Quiz
Maintenance Selinexor for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer
08/08/2024
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance...
08/08/2024
Oncology
Quiz
Recommended Dostarlimab Dose for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/08/2024
Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...
Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...
Based on results from the phase...
08/08/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Maintenance Selinexor Showed Promise for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer
07/23/2024
Subgroup analysis results from the phase 3 SIENDO study found selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer.
Subgroup analysis results from the phase 3 SIENDO study found selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer.
Subgroup analysis results from...
07/23/2024
Oncology
News
Dostarlimab Plus Chemotherapy as New Standard of Care for Patients With Primary Advanced or Recurrent Endometrial Cancer
07/22/2024
Second interim analysis results from the phase 3 RUBY trial demonstrated that the addition of dostarlimab to chemotherapy improved overall survival among patients with primary advanced or recurrent endometrial cancer.
Second interim analysis results from the phase 3 RUBY trial demonstrated that the addition of dostarlimab to chemotherapy improved overall survival among patients with primary advanced or recurrent endometrial cancer.
Second interim analysis results...
07/22/2024
Oncology
FDA Approval
FDA Approves Pembrolizumab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
06/17/2024
Allison Casey
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase...
06/17/2024
Oncology
FDA Approval
FDA Approves Durvalumab Plus Carboplatin and Paclitaxel for Patients With Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer
06/17/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 DUO-E trial, the FDA has approved durvalumab plus carboplatin and paclitaxel followed by durvalumab maintenance for patients with primary advanced or recurrent mismatch repair deficient endometrial cancer.
Based on results from the phase 3 DUO-E trial, the FDA has approved durvalumab plus carboplatin and paclitaxel followed by durvalumab maintenance for patients with primary advanced or recurrent mismatch repair deficient endometrial cancer.
Based on results from the phase...
06/17/2024
Oncology
Quiz
Post-Progression Median PFS With Monotherapy for Endometrial Cancer
04/10/2024
What was the median progression-free survival for endometrial cancer treated with monotherapy after disease progression following initial treatment?
What was the median progression-free survival for endometrial cancer treated with monotherapy after disease progression following initial treatment?
What was the median...
04/10/2024
Oncology
News
Molecular Classification to Predict Prognosis and Relapse Patterns Among Patients With Low/Intermediate-Risk Endometrial Cancer
02/13/2024

Stephanie Holland 

Stephanie Holland 
Results from a retrospective cohort study found that molecular classification can predict prognosis and relapse patterns among patients with low or intermediate-risk endometrial cancer.
Results from a retrospective cohort study found that molecular classification can predict prognosis and relapse patterns among patients with low or intermediate-risk endometrial cancer.
Results from a retrospective...
02/13/2024
Oncology
News
Selinexor Maintenance Therapy Improved PFS Among Patients With TP53 Wild-Type Advanced or Recurrent Endometrial Cancer
10/12/2023

Stephanie Holland 

Stephanie Holland 
Results from an exploratory analysis of the ENGOT-EN5/GOG-3055/SIENDO study identified that selinexor maintenance therapy improved PFS among patients with TP53 wild-type advanced or recurrent endometrial cancer.
Results from an exploratory analysis of the ENGOT-EN5/GOG-3055/SIENDO study identified that selinexor maintenance therapy improved PFS among patients with TP53 wild-type advanced or recurrent endometrial cancer.
Results from an exploratory...
10/12/2023
Oncology
News
Statistical Significance, Prognostic Precision of 2023 FIGO Staging System for Pre-Treated, Early-Stage Endometrial Cancer
09/19/2023

Stephanie Holland 

Stephanie Holland 
According to results of a retrospective study, the 2023 FIGO staging system led to statistically significant stage shifts and higher prognostic precision among patients with pre-treated, early-stage endometrial cancer.
According to results of a retrospective study, the 2023 FIGO staging system led to statistically significant stage shifts and higher prognostic precision among patients with pre-treated, early-stage endometrial cancer.
According to results of a...
09/19/2023
Oncology

Advertisement

News

FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Maintenance Selinexor Showed Promise for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer
07/23/2024
Subgroup analysis results from the phase 3 SIENDO study found selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer.
Subgroup analysis results from the phase 3 SIENDO study found selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer.
Subgroup analysis results from...
07/23/2024
Oncology
News
Dostarlimab Plus Chemotherapy as New Standard of Care for Patients With Primary Advanced or Recurrent Endometrial Cancer
07/22/2024
Second interim analysis results from the phase 3 RUBY trial demonstrated that the addition of dostarlimab to chemotherapy improved overall survival among patients with primary advanced or recurrent endometrial cancer.
Second interim analysis results from the phase 3 RUBY trial demonstrated that the addition of dostarlimab to chemotherapy improved overall survival among patients with primary advanced or recurrent endometrial cancer.
Second interim analysis results...
07/22/2024
Oncology
FDA Approval
FDA Approves Pembrolizumab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
06/17/2024
Allison Casey
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase...
06/17/2024
Oncology
FDA Approval
FDA Approves Durvalumab Plus Carboplatin and Paclitaxel for Patients With Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer
06/17/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 DUO-E trial, the FDA has approved durvalumab plus carboplatin and paclitaxel followed by durvalumab maintenance for patients with primary advanced or recurrent mismatch repair deficient endometrial cancer.
Based on results from the phase 3 DUO-E trial, the FDA has approved durvalumab plus carboplatin and paclitaxel followed by durvalumab maintenance for patients with primary advanced or recurrent mismatch repair deficient endometrial cancer.
Based on results from the phase...
06/17/2024
Oncology
News
Molecular Classification to Predict Prognosis and Relapse Patterns Among Patients With Low/Intermediate-Risk Endometrial Cancer
02/13/2024

Stephanie Holland 

Stephanie Holland 
Results from a retrospective cohort study found that molecular classification can predict prognosis and relapse patterns among patients with low or intermediate-risk endometrial cancer.
Results from a retrospective cohort study found that molecular classification can predict prognosis and relapse patterns among patients with low or intermediate-risk endometrial cancer.
Results from a retrospective...
02/13/2024
Oncology
News
Selinexor Maintenance Therapy Improved PFS Among Patients With TP53 Wild-Type Advanced or Recurrent Endometrial Cancer
10/12/2023

Stephanie Holland 

Stephanie Holland 
Results from an exploratory analysis of the ENGOT-EN5/GOG-3055/SIENDO study identified that selinexor maintenance therapy improved PFS among patients with TP53 wild-type advanced or recurrent endometrial cancer.
Results from an exploratory analysis of the ENGOT-EN5/GOG-3055/SIENDO study identified that selinexor maintenance therapy improved PFS among patients with TP53 wild-type advanced or recurrent endometrial cancer.
Results from an exploratory...
10/12/2023
Oncology
News
Statistical Significance, Prognostic Precision of 2023 FIGO Staging System for Pre-Treated, Early-Stage Endometrial Cancer
09/19/2023

Stephanie Holland 

Stephanie Holland 
According to results of a retrospective study, the 2023 FIGO staging system led to statistically significant stage shifts and higher prognostic precision among patients with pre-treated, early-stage endometrial cancer.
According to results of a retrospective study, the 2023 FIGO staging system led to statistically significant stage shifts and higher prognostic precision among patients with pre-treated, early-stage endometrial cancer.
According to results of a...
09/19/2023
Oncology
News
Molecular Classification Predicts Radiotherapy Benefit in Early-Stage Endometrioid Endometrial Cancer
08/29/2023

Stephanie Holland 

Stephanie Holland 
According to an analysis of data from the PORTEC-1 and PORTEC-2 trials, molecular classification can predict response to radiotherapy in early-stage endometrioid endometrial cancer.
According to an analysis of data from the PORTEC-1 and PORTEC-2 trials, molecular classification can predict response to radiotherapy in early-stage endometrioid endometrial cancer.
According to an analysis of data...
08/29/2023
Oncology
News
Selinexor Maintenance Therapy Demonstrated Durable PFS Benefit Among Patients With Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
08/10/2023

Stephanie Holland 

Stephanie Holland 
According to long-term follow-up results from the phase 3 SIENDO trial, selinexor maintenance prior to systemic therapy showed durable PFS benefit among patients with advanced or recurrent TP53wt endometrial cancer.
According to long-term follow-up results from the phase 3 SIENDO trial, selinexor maintenance prior to systemic therapy showed durable PFS benefit among patients with advanced or recurrent TP53wt endometrial cancer.
According to long-term follow-up...
08/10/2023
Oncology

Interactive Features

Quiz
Maintenance Selinexor for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer
08/08/2024
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance...
08/08/2024
Oncology
Quiz
Recommended Dostarlimab Dose for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/08/2024
Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...
Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...
Based on results from the phase...
08/08/2024
Oncology
Quiz
Post-Progression Median PFS With Monotherapy for Endometrial Cancer
04/10/2024
What was the median progression-free survival for endometrial cancer treated with monotherapy after disease progression following initial treatment?
What was the median progression-free survival for endometrial cancer treated with monotherapy after disease progression following initial treatment?
What was the median...
04/10/2024
Oncology
Quiz
Quiz: Does Post-Operative Chemotherapy and Radiation Improve OS in Endometrial Cancer?
08/10/2021
True or false: For high-risk patients with stage I endometrial cancer, post-operative systemic chemotherapy and radiotherapy was shown to improve overall survival.
True or false: For high-risk patients with stage I endometrial cancer, post-operative systemic chemotherapy and radiotherapy was shown to improve overall survival.
True or false: For high-risk...
08/10/2021
Oncology
Test Your Knowledge
Quiz: Which Disease is the Leading Cause of Death for Patients Who Survive Endometrial Cancer?
07/29/2021
For survivors of endometrial cancer, which disease is the leading cause of death?
For survivors of endometrial cancer, which disease is the leading cause of death?
For survivors of endometrial...
07/29/2021
Oncology
Quiz
Quiz: What Type of Testing Effectively Identifies Lynch Syndrome Diagnoses?
07/01/2021
According to a recent study that evaluated an alternative approach to tumor-based screenings, which type of testing effectively identifies and diagnoses patients with Lynch Syndrome?
According to a recent study that evaluated an alternative approach to tumor-based screenings, which type of testing effectively identifies and diagnoses patients with Lynch Syndrome?
According to a recent study that...
07/01/2021
Oncology
doc
Test Your Knowledge
Quiz: Upfront MGPT vs Tumor Screening for Lynch Syndrome in Endometrial Cancer
06/02/2021
True or False: Upfront multi-gene panel testing in patients with endometrial cancer has been shown to detect cases of Lynch syndrome not identified by tumor screening.
True or False: Upfront multi-gene panel testing in patients with endometrial cancer has been shown to detect cases of Lynch syndrome not identified by tumor screening.
True or False: Upfront...
06/02/2021
Oncology
Test Your Knowledge
Quiz: A Common Thread in Rising Endometrial Cases in US Women
05/29/2021
Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?
Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?
Quiz: Among young adult women in...
05/29/2021
Oncology
Test Your Knowledge
Quiz: Is Upfront Germline Genetic Testing Encouraged in Endometrial Cancer?
05/28/2021
True or False: Experts opine that upfront germline genetic testing should be considered for patients with any and all solid tumors, including endometrial cancer.
True or False: Experts opine that upfront germline genetic testing should be considered for patients with any and all solid tumors, including endometrial cancer.
True or False: Experts opine...
05/28/2021
Oncology
Test Your Knowledge
Quiz: Is Intensive Follow-Up of Patients Treated for Endometrial Cancer Beneficial?
05/28/2021
True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.
True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.
True or False: Study findings...
05/28/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Maintenance Selinexor Showed Promise for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer
07/23/2024
Subgroup analysis results from the phase 3 SIENDO study found selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer.
Subgroup analysis results from the phase 3 SIENDO study found selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer.
Subgroup analysis results from...
07/23/2024
Oncology
News
Dostarlimab Plus Chemotherapy as New Standard of Care for Patients With Primary Advanced or Recurrent Endometrial Cancer
07/22/2024
Second interim analysis results from the phase 3 RUBY trial demonstrated that the addition of dostarlimab to chemotherapy improved overall survival among patients with primary advanced or recurrent endometrial cancer.
Second interim analysis results from the phase 3 RUBY trial demonstrated that the addition of dostarlimab to chemotherapy improved overall survival among patients with primary advanced or recurrent endometrial cancer.
Second interim analysis results...
07/22/2024
Oncology
FDA Approval
FDA Approves Pembrolizumab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
06/17/2024
Allison Casey
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase...
06/17/2024
Oncology
FDA Approval
FDA Approves Durvalumab Plus Carboplatin and Paclitaxel for Patients With Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer
06/17/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 DUO-E trial, the FDA has approved durvalumab plus carboplatin and paclitaxel followed by durvalumab maintenance for patients with primary advanced or recurrent mismatch repair deficient endometrial cancer.
Based on results from the phase 3 DUO-E trial, the FDA has approved durvalumab plus carboplatin and paclitaxel followed by durvalumab maintenance for patients with primary advanced or recurrent mismatch repair deficient endometrial cancer.
Based on results from the phase...
06/17/2024
Oncology
News
Molecular Classification to Predict Prognosis and Relapse Patterns Among Patients With Low/Intermediate-Risk Endometrial Cancer
02/13/2024

Stephanie Holland 

Stephanie Holland 
Results from a retrospective cohort study found that molecular classification can predict prognosis and relapse patterns among patients with low or intermediate-risk endometrial cancer.
Results from a retrospective cohort study found that molecular classification can predict prognosis and relapse patterns among patients with low or intermediate-risk endometrial cancer.
Results from a retrospective...
02/13/2024
Oncology
News
Selinexor Maintenance Therapy Improved PFS Among Patients With TP53 Wild-Type Advanced or Recurrent Endometrial Cancer
10/12/2023

Stephanie Holland 

Stephanie Holland 
Results from an exploratory analysis of the ENGOT-EN5/GOG-3055/SIENDO study identified that selinexor maintenance therapy improved PFS among patients with TP53 wild-type advanced or recurrent endometrial cancer.
Results from an exploratory analysis of the ENGOT-EN5/GOG-3055/SIENDO study identified that selinexor maintenance therapy improved PFS among patients with TP53 wild-type advanced or recurrent endometrial cancer.
Results from an exploratory...
10/12/2023
Oncology
News
Statistical Significance, Prognostic Precision of 2023 FIGO Staging System for Pre-Treated, Early-Stage Endometrial Cancer
09/19/2023

Stephanie Holland 

Stephanie Holland 
According to results of a retrospective study, the 2023 FIGO staging system led to statistically significant stage shifts and higher prognostic precision among patients with pre-treated, early-stage endometrial cancer.
According to results of a retrospective study, the 2023 FIGO staging system led to statistically significant stage shifts and higher prognostic precision among patients with pre-treated, early-stage endometrial cancer.
According to results of a...
09/19/2023
Oncology
News
Molecular Classification Predicts Radiotherapy Benefit in Early-Stage Endometrioid Endometrial Cancer
08/29/2023

Stephanie Holland 

Stephanie Holland 
According to an analysis of data from the PORTEC-1 and PORTEC-2 trials, molecular classification can predict response to radiotherapy in early-stage endometrioid endometrial cancer.
According to an analysis of data from the PORTEC-1 and PORTEC-2 trials, molecular classification can predict response to radiotherapy in early-stage endometrioid endometrial cancer.
According to an analysis of data...
08/29/2023
Oncology
News
Selinexor Maintenance Therapy Demonstrated Durable PFS Benefit Among Patients With Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
08/10/2023

Stephanie Holland 

Stephanie Holland 
According to long-term follow-up results from the phase 3 SIENDO trial, selinexor maintenance prior to systemic therapy showed durable PFS benefit among patients with advanced or recurrent TP53wt endometrial cancer.
According to long-term follow-up results from the phase 3 SIENDO trial, selinexor maintenance prior to systemic therapy showed durable PFS benefit among patients with advanced or recurrent TP53wt endometrial cancer.
According to long-term follow-up...
08/10/2023
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement